

PRESS RELEASE

The Oncidium Foundation and IAEA Partner to Expand Access to Targeted Radionuclide Therapy for Cancer Care Worldwide

VIENNA, AUSTRIA – September 16, 2025 – The Oncidium foundation, an independent non-profit organization dedicated to ensuring equal access to radioligand therapy for cancer care, today announced a new collaboration agreement with the International Atomic Energy Agency (IAEA). This landmark agreement, signed under the IAEA's [Rays of Hope](#) flagship initiative, is a significant step toward making advanced Targeted Radionuclide Therapy (TRT) available to patients in underserved regions.

"By working with the Oncidium foundation under the Rays of Hope initiative, we are strengthening global efforts to ensure that advanced cancer care, including nuclear medicine, is not limited to a few but made available to all who need it," **said Rafael Mariano Grossi, Director General of the IAEA.**

The Practical Arrangement between the Oncidium foundation and the IAEA aims to directly support these efforts by raising awareness, building capacity, and fostering partnerships to expand access to TRT.

"TRT is a precise cancer treatment, but significant production, regulatory, logistical, and economic barriers limit its global availability. The IAEA's Rays of Hope initiative's goal is to improve access to nuclear medicine, radiology and radiotherapy within a quality management and safety framework. It supports access and prioritizes high-impact, cost-effective radiation medicine interventions that meet national needs," **explained May Abdel-Wahab, Director of the IAEA Division of Human Health.**

"Our collaboration with the IAEA through Rays of Hope is a testament to the power of partnership," **said Rebecca Lo bue, CEO of the Oncidium foundation.** *"By working together, we can turn the promise of radioligand therapy into a global reality, ensuring that advanced treatments reach those who need them most."*

The announcement was a key highlight of the Oncidium foundation's side event "Raising Hope: Enhancing Global Access to Personalized Cancer Care - Belgium and IAEA Partner to Advance Targeted Radionuclide Therapy", which was held during the IAEA's 69th General Conference and showcased the foundation's vital collaborations with key Belgian partners, including PanTera and SCK-CEN for radiopharmaceuticals production and the Jules Bordet Institute for clinical applications. A special focus was placed on expanding access to alpha-therapy. These joint efforts aim to bridge the gap between innovation and accessibility for cancer patients everywhere.

About the Oncidium foundation: The Oncidium foundation is a nonprofit organization dedicated to advancing global access to radioligand therapy for cancer care. The foundation's priorities include raising awareness about radiotheranostics among patients and physicians, supporting and financing



the development of new radiopharmaceuticals for therapy, promoting clinical best practices, and improving access to radiotheranostics globally.

For more information, visit <http://www.oncidiumfoundation.org>.

About the International Atomic Energy Agency (IAEA): The International Atomic Energy Agency is the world's center for cooperation in the nuclear field. Established in 1957, the IAEA works with its Member States and partners worldwide to promote the safe, secure, and peaceful use of nuclear technologies. Its mission is guided by the vision of "Atoms for Peace and Development," which includes a strong focus on using nuclear science for human health, including the diagnosis and treatment of cancer. Through its [human health programme](#), the IAEA assists countries in building and strengthening their capacity to use nuclear techniques to address a wide range of health challenges.

For media inquiries, please contact: thais@oncidium-life.org

